Nuo Therapeutics, Inc.

Nuo Therapeutics, Inc. is a commercial-stage medical device company focused on developing and commercializing cell-based biological therapies for chronic wound care. Its primary commercial product is the Aurix System, a point-of-care medical device that processes a patient's peripheral blood into an autologous platelet-rich plasma hematogel to facilitate tissue repair and healing in exuding wounds, such as diabetic foot ulcers. The company's customer base consists primarily of private practice physicians, hospital outpatient wound care clinics, and its distribution partner, Smith+Nephew, which distributes a private-label version of the product.

The company operates predominantly within the United States, utilizing a commercial team of four senior employees alongside contractual partnerships with more than 200 third-party entities and sales representatives to market its offerings. Nuo Therapeutics maintains ten full-time employees and is headquartered with its principal offices located in Houston, Texas.

Summary of the business section of Nuo Therapeutics's latest annual report, written by StockData.

“The Company had 10 full-time employees as of December 31, 2025 which are all compensated as salaried employees.”